Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice

EMBO Molecular Medicine

Volumn 7, Issue 12, 2015, Pages 1547-1564

  Valenza, Marta ^a   Chen, Jane Y ^b   Di Paolo, Eleonora ^a   Ruozi, Barbara ^c   Belletti, Daniela ^c   Ferrari Bardile, Costanza ^a   Leoni, Valerio ^d,e   Caccia, Claudio ^d   Brilli, Elisa ^a   Di Donato, Stefano ^d   Boido, Marina M ^f   Vercelli, Alessandro ^f   Vandelli, Maria A ^c   Forni, Flavio ^c   Cepeda, Carlos ^b   Levine, Michael S ^b   Tosi, Giovanni ^c   Cattaneo, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e OSPEDALE DI CIRCOLO   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

Cholesterol; Cognition; Huntington's disease; Nanoparticles; Synapses

Indexed keywords

CHOLESTEROL; GLYCOPEPTIDE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; GLIA CELL; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUPPLEMENTATION; SYNAPSE; SYSTEMIC THERAPY; ANIMAL; COGNITION; DISEASE MODEL; DRUG EFFECTS; HUNTINGTON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; CHOLESTEROL; COGNITION; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MICE; NANOPARTICLES; NEURONS; SYNAPSES;

EID: 84954217540     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201505413     Document Type: Article

References (85)

1. Barenholz Y (2012) Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release 160: 117-134
2. Barker GR, Warburton EC (2011) When is the hippocampus involved in recognition memory? J Neurosci 31: 10721-10731
3. Belletti D, Tosi G, Forni F, Gamberini MC, Baraldi C, Vandelli MA, Ruozi B (2012) Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. Int J Pharm 436: 753-763
4. Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23: 961-969
5. Cepeda C, Starling AJ, Wu N, Nguyen OK, Uzgil B, Soda T, Andre VM, Ariano MA, Levine MS (2004) Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 78: 855-867
6. Chang KH, Wu YR, Chen YC, Chen CM (2015) Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. Brain Behav Immun 44: 121-127
7. Conforti P, Camnasio S, Mutti C, Valenza M, Thompson M, Fossale E, Zeitlin S, MacDonald ME, Zuccato C, Cattaneo E (2013) Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. Neurobiol Dis 50: 160-170
8. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F (2005) Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release 108: 84-96
9. Cummings DM, Milnerwood AJ, Dallerac GM, Waights V, Brown JY, Vatsavayai SC, Hirst MC, Murphy KP (2006) Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 15: 2856-2868
10. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161: 505-522
11. Darvas M, Palmiter RD (2009) Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proc Natl Acad Sci USA 106: 14664-14669
12. Dason JS, Smith AJ, Marin L, Charlton MP (2010) Vesicular sterols are essential for synaptic vesicle cycling. J Neurosci 30: 15856-15865
13. Dason JS, Smith AJ, Marin L, Charlton MP (2014) Cholesterol and F-actin are required for clustering of recycling synaptic vesicle proteins in the presynaptic plasma membrane. J Physiol 592: 621-633
14. Dietschy JM, Turley SD (2004) Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45: 1375-1397
15. Frank C, Giammarioli AM, Pepponi R, Fiorentini C, Rufini S (2004) Cholesterol perturbing agents inhibit NMDA-dependent calcium influx in rat hippocampal primary culture. FEBS Lett 566: 25-29
16. Frank C, Rufini S, Tancredi V, Forcina R, Grossi D, D'Arcangelo G (2008) Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Exp Neurol 212: 407-414
17. Freeman W, Morton AJ (2004) Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res Bull 63: 45-55
18. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 37: 48-57
19. Gardoni F, Mauceri D, Malinverno M, Polli F, Costa C, Tozzi A, Siliquini S, Picconi B, Cattabeni F, Calabresi P et al (2009) Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J Neurosci 29: 669-677
20. Gimpl G, Gehrig-Burger K (2007) Cholesterol reporter molecules. Biosci Rep 27: 335-358
21. Glynn D, Bortnick RA, Morton AJ (2003) Complexin II is essential for normal neurological function in mice. Hum Mol Genet 12: 2431-2448
22. Gosk S, Vermehren C, Storm G, Moos T (2004) Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 24: 1193-1204
23. Hara Y, Waters EM, McEwen BS, Morrison JH (2015) Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev 95: 785-807
24. HDCRG (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983
25. Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23: 3262-3271
26. Huttner WB, Zimmerberg J (2001) Implications of lipid microdomains for membrane curvature, budding and fission. Curr Opin Cell Biol 13: 478-484
27. Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS et al (2009) Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 29: 2414-2427
28. Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, Jahn R (2001) SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J 20: 2202-2213
29. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW (1996) Executive and mnemonic functions in early Huntington's disease. Brain 119(Pt 5): 1633-1645
30. Lawrence AD, Watkins LH, Sahakian BJ, Hodges JR, Robbins TW (2000) Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits. Brain 123(Pt 7): 1349-1364
31. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Bjorkhem I et al (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131: 2851-2859
32. Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS, Group P-Hs (2013) Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis 55: 37-43
33. Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF (2004) Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 27: 691-697
34. Linetti A, Fratangeli A, Taverna E, Valnegri P, Francolini M, Cappello V, Matteoli M, Passafaro M, Rosa P (2010) Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci 123: 595-605
35. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278: 22980-22988
36. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506
37. Martin MG, Ahmed T, Korovaichuk A, Venero C, Menchon SA, Salas I, Munck S, Herreras O, Balschun D, Dotti CG (2014a) Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents. EMBO Mol Med 6: 902-917
38. Martin MG, Pfrieger F, Dotti CG (2014b) Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep 15: 1036-1052
39. Marullo M, Valenza M, Leoni V, Caccia C, Scarlatti C, De MA, Zuccato C, Di Donato S, Carafoli E, Cattaneo E (2012) Pitfalls in the detection of cholesterol in Huntington's disease models. PLoS Curr 4: e505886e505889a501968
40. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357
41. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR et al (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65: 178-190
42. Milnerwood AJ, Raymond LA (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci 33: 513-523
43. Minost A, Delaveau J, Bolzinger MA, Fessi H, Elaissari A (2012) Nanoparticles via nanoprecipitation process. Recent Pat Drug Deliv Formul 6: 250-258
44. Morton AJ, Edwardson JM (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem 76: 166-172
45. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J Control Release 125: 193-209
46. Orth M, Schippling S, Schneider SA, Bhatia KP, Talelli P, Tabrizi SJ, Rothwell JC (2010) Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J Neurol Neurosurg Psychiatry 81: 267-270
47. Paratcha G, Ibanez CF (2002) Lipid rafts and the control of neurotrophic factor signaling in the nervous system: variations on a theme. Curr Opin Neurobiol 12: 542-549
48. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ et al (2008) Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79: 874-880
49. Paulsen JS, Long JD (2014) Onset of Huntington's disease: can it be purely cognitive? Mov Disord 29: 1342-1350
50. Paxinos G, Franklin KBJ (2008) Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates, 3rd edn. Waltham, MA: Academic Press
51. Pfrieger FW (2003) Role of cholesterol in synapse formation and function. Biochim Biophys Acta 1610: 271-280
52. Reim K, Mansour M, Varoqueaux F, McMahon HT, Sudhof TC, Brose N, Rosenmund C (2001) Complexins regulate a late step in Ca2 + -dependent neurotransmitter release. Cell 104: 71-81
53. Renner M, Choquet D, Triller A (2009) Control of the postsynaptic membrane viscosity. J Neurosci 29: 2926-2937
54. Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10: 204-216
55. Schippling S, Schneider SA, Bhatia KP, Munchau A, Rothwell JC, Tabrizi SJ, Orth M (2009) Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol Psychiatry 65: 959-965
56. Sethi A, Sher M, Akram MR, Karim S, Khiljee S, Sajjad A, Shah SN, Murtaza G (2013) Albumin as a drug delivery and diagnostic tool and its market approved products. Acta Pol Pharm 70: 597-600
57. Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G et al (2013) Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res 19: 1806-1815
58. Shive MS, Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28: 5-24
59. Suzuki R, Ferris HA, Chee MJ, Maratos-Flier E, Kahn CR (2013) Reduction of the cholesterol sensor SCAP in the brains of mice causes impaired synaptic transmission and altered cognitive function. PLoS Biol 11: e1001532
60. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, Cheng MM, Decuzzi P, Tour JM, Robertson F et al (2008) Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 3: 151-157
61. Thiele C, Hannah MJ, Fahrenholz F, Huttner WB (2000) Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol 2: 42-49
62. del Toro D, Xifro X, Pol A, Humbert S, Saudou F, Canals JM, Alberch J (2010) Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. J Neurochem 115: 153-167
63. Tosi G, Rivasi F, Gandolfi F, Costantino L, Vandelli MA, Forni F (2005) Conjugated poly(D, L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 26: 4189-4195
64. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F (2007) Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 122: 1-9
65. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 5: 155-174
66. Tosi G, Vergoni AV, Ruozi B, Bondioli L, Badiali L, Rivasi F, Costantino L, Forni F, Vandelli MA (2010) Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J Control Release 145: 49-57
67. Tosi G, Bondioli L, Ruozi B, Badiali L, Severini GM, Biffi S, De Vita A, Bortot B, Dolcetta D, Forni F et al (2011a) NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. J Neural Transm 118: 145-153
68. Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, Ruozi B, Forni F, Vandelli MA (2011b) Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine 6: 423-436
69. Tosi G, Badiali L, Ruozi B, Vergoni AV, Bondioli L, Ferrari A, Rivasi F, Forni F, Vandelli MA (2012) Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine 7: 365-382
70. Tosi G, Vilella A, Chhabra R, Schmeisser MJ, Boeckers TM, Ruozi B, Vandelli MA, Forni F, Zoli M, Grabrucker AM (2014) Insight on the fate of CNS-targeted nanoparticles. Part II: intercellular neuronal cell-to-cell transport. J Control Release 177: 96-107
71. Trager U, Andre R, Magnusson-Lind A, Miller JR, Connolly C, Weiss A, Grueninger S, Silajdzic E, Smith DL, Leavitt BR et al (2014) Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiol Dis 73C: 388-398
72. Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG, Pagano RE, McMurray CT (2006) Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet 15: 3578-3591
73. Trushina E, Canaria CA, Lee DY, McMurray CT (2014) Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo. Hum Mol Genet 23: 129-144
74. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M et al (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 25: 9932-9939
75. Valenza M, Cattaneo E (2006) Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog Neurobiol 80: 165-176
76. Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E (2007a) Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet 16: 2187-2198
77. Valenza M, Leoni V, Tarditi A, Mariotti C, Bjorkhem I, Di Donato S, Cattaneo E (2007b) Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 28: 133-142
78. Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O et al (2010) Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 30: 10844-10850
79. Valenza M, Marullo M, Di Paolo E, Cesana E, Zuccato C, Biella G, Cattaneo E (2015) Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease. Cell Death Differ 22: 690-702
80. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L (2009) Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine 5: 369-377
81. Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, Boeckers TM, Forni F, Zoli M (2014) Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. J Control Release 174: 195-201
82. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703
83. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57: 369-384
84. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90: 905-981
85. Zuccato C, Cattaneo E (2014) Huntington's disease. Handb Exp Pharmacol 220: 357-409